ICU入住48小时内死亡患者的生命支持治疗限制:一项法国多中心观察性探索研究
该研究为法国12个ICU的回顾性多中心观察性探索研究,纳入2022至2023年连续入住ICU并在48小时内死亡的患者。1615例入住患者中100例(6.2%)48小时内死亡,其中62例有生命支持治疗限制(LST-L)决策。LST-L组年龄更大(72岁 vs 63岁,p=0.002)、Charlson合并症指数更高(5.5 vs 4.0,p<0.001),管理侵入性更低。多变量分析显示男性患者接受LST-L决策的可能性更低(OR 0.35,95%CI 0.13-0.93,p=0.03)。多数医师认为LST-L决策是共识性的,但护士中比例较低;患者意愿在决策中很少被考虑,限时试验很少使用。
要点
- ICU入住48小时内死亡患者中,62/100例(62%)死亡前已有生命支持治疗限制决策,决策无统一方案,由主治重症医师酌情决定。
- LST-L组年龄72岁(64-77.8岁)vs 全治疗组63岁(59.0-69.8岁),p=0.002;Charlson合并症指数5.5(2.0-8.0)vs 4.0(2.0-5.0),p<0.001。
- 多变量分析中男性患者接受LST-L决策的可能性更低(OR 0.35,95%CI 0.13-0.93,p=0.03)。
- 100例中28例被重症医师回顾性认为ICU入住并非最合适选择;患者意愿在LST-L决策中很少被考虑,限时试验很少使用。
- 三分之二的LST-L决策在值班时段做出;多数医师认为决策是共识性的,但护士中持此看法的比例较小。
适用人群与场景
- 法国12个ICU在2022至2023年研究期间连续纳入的、入住ICU后48小时内死亡的患者。
- LST-L决策无方案指导,由主治重症医师酌情决定。
研究设计与关键结果
- 研究类型:回顾性、观察性、多中心研究,数据在患者死亡后立即按预设标准收集,共12个ICU参与。
- 研究期间参与ICU共收治1615例患者,其中100例(6.2%)在48小时内死亡,62例有LST-L决策。
- LST-L组年龄72岁(64-77.8岁)vs 全治疗组63岁(59.0-69.8岁),p=0.002;Charlson合并症指数5.5(2.0-8.0)vs 4.0(2.0-5.0),p<0.001;LST-L组管理侵入性更低。
- 多变量分析:男性患者接受LST-L决策的可能性更低(OR 0.35,95%CI 0.13-0.93,p=0.03)。
- 100例中28例被重症医师回顾性认为ICU入住并非最合适选择;患者意愿在LST-L决策中很少被考虑;限时试验很少使用;三分之二的LST-L决策在值班时段做出。
- 多数医师认为LST-L决策是共识性的,但护士中持此看法的比例较小。
证据类型、等级与局限
- 证据类型:回顾性、观察性、多中心探索性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要更好地考虑患者意愿,并加强ICU医师与护理人员之间的沟通,以确保提供适当医疗——即使患者意愿未知且ICU入住的替代方案不明确时也是如此。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The occurrence of death shortly after ICU admission raises concerns about the appropriateness of providing intensive care to frail patients-many of whom are subsequently subject to decisions to limit life-supporting treatment limitation (LST-L). The proportion of patients who die early and are affected by such limitations remains unknown.
OBJECTIVES: The primary objective was to determine the proportion of patients with a decision of LST-L among patients who died within 48 hours after ICU admission. We also conducted analyses to identify variables associated with LST-L and collected staff perceptions.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective, observational, multicenter study with data collected immediately after the patient's death, according to predefined criteria. The study was conducted in 12 ICUs in France. Consecutive patients who died within 48 hours of ICU admission during the study period, in 2022-2023, were included. LST-L decisions were not guided by protocols but were at the discretion of the attending intensivists.
MAIN OUTCOMES AND MEASURES: Of 1615 patients admitted to the participating ICUs during the study period, 100 died (6.2%) within 48 hours, including 62 with LST-L.
RESULTS: In the LST-L group, age was significantly older (72 yr [64-77.8 yr] vs. 63 yr [59.0-69.8 yr]; p = 0.002), Charlson Comorbidity Index significantly higher (5.5 [2.0-8.0] vs. 4.0 [2.0-5.0]; p < 0.001), and management less invasive compared with the full-care group. By multivariable analysis, male patients were less likely to have LST-L decisions (odds ratio, 0.35; 95% CI, 0.13-0.93; p = 0.03). Most physicians, but a smaller proportion of nurses, perceived LST-L decisions as consensual. For 28 of 100 patients, the intensivist retrospectively deemed the ICU admission not the most suitable option. Patient wishes were rarely considered when making LST-L decisions. Time-limited trials were rarely used. Two-thirds of LST-L decisions were made during on-call hours.
CONCLUSIONS AND RELEVANCE: Deaths occurring shortly after ICU admission were usually preceded by LST-L decisions. Efforts are needed to better consider patients' wishes and to strengthen communication between ICU physicians and nursing staff, to ensure appropriate care-even when patients' wishes are unknown and alternatives to ICU admission are not straightforward. Such rare and sometimes unforeseeable cases may also reflect unspoken preferences of patients or their families.
参考来源
- Nouvel A, Leprovost P, Larrat C, et al. Life-Supporting Treatment Limitations in Patients Who Die Within 48 Hours After ICU Admission: A French, Multicenter, Observational, Exploratory Study. Crit Care Explor. 2025. PMID: 40767543. doi:10.1097/CCE.0000000000001300
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。